Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization
Objective It has been proved that glucagon-like peptide-1 receptor (GLP1R) agonists have positive effects on renal outcomes in diabetic patients. However, it remains unknown whether GLP1R agonists could provide similar protection against other kidney diseases.Methods We performed two-sample Mendelia...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis Group
2025-12-01
|
| シリーズ: | Renal Failure |
| 主題: | |
| オンライン･アクセス: | https://www.tandfonline.com/doi/10.1080/0886022X.2025.2478488 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|